The Pharmaceutical Industry is pouring resources into the growing political fight over Generic coronavirus vaccines. Newly filed disclosure forms from the first quarter of 2021 show that over 100 lobbyists have been appointed and mobilized to contact lawmakers and members of the Biden Administration.The information got surveyed which said that the Lobbyists have been urging the government to oppose a proposed temporary waiver on intellectual property rights by the World Trade Organization that would allow Generic vaccines to be produced on the global stage. In addition, several trade groups funded by Pharmaceutical industries have focused closely on beating the bush and fighting against the Generic proposal.
In response to the waiver, a coalition of countries, led by India and South Africa, have petitioned the WTO to temporarily suspend intellectual property rights on coronavirus-related medicine products. In response, the US is extending its support by providing raw materials to India so that Generic vaccines can be rapidly manufactured.
If the intellectual property rights get granted, local pharmaceutical plants could be granted compulsory licenses to produce Coronavirus vaccines without the threat of being sued by the license holder. It could pose a threat to the countries that do not have adequate supply and are suffering immensely because of the lack of domestic production of vaccines.